Research Article
Favorable Effect of Anti-TNF Therapy on Insulin Sensitivity in Nonobese, Nondiabetic Patients with Inflammatory Bowel Disease
Table 1
Characteristics of patients from the two therapy groups (results presented as mean ± SD).
| | AMSs () | Anti-TNF () | value |
| | Age (years) | 38.7 ± 12.5 | 33.6 ± 8.8 | ns | | Gender | 16 M/7 F | 9 M/9 F | ns | | BMI (kg/m2) | 23.1 ± 1.7 | 23.3 ± 3.4 | ns | | Fasting glucose (mg/dl) | 93.4 ± 14.9 | 88 ± 10.7 | ns | | Insulin (μIU/ml) | 12.1 ± 6.6 | 10.9 ± 7.9 | ns | | C-peptide (ng/ml) | 2.2 ± 1.4 | 1.9 ± 0.9 | ns | | HbA1c (%) | 5.3 ± 0.4 | 5.2 ± 0.3 | ns | | Cholesterol (mg/dl) | 162.8 ± 34.3 | 168.6 ± 32.7 | ns | | HDL (mg/dl) | 53.8 ± 20.3 | 57.5 ± 15.7 | ns | | LDL (mg/dl) | 90.7 ± 24.4 | 95.8 ± 28.7 | ns | | Triglycerides (mg/dl) | 90.8 ± 61.3 | 75.8 ± 37.6 | ns | | CRP (mg/l) | 4.9 ± 6.1 | 3 ± 5.4 | ns | | HOMA-IR | 3.1 ± 1.9 | 2.77 ± 2 | ns |
|
|
AMSs: aminosalicylates; BMI: body mass index; CRP: C-reactive protein; HDL: high-density lipoprotein; HOMA-IR: homeostatic model assessment insulin resistance; LDL: low-density lipoprotein; TNFα: tumor necrosis factor alpha.
|
